- SID Score
- 6.8/10
- Fair value
- $509.31
- Generated
- Sep 17, 2026
- Model
- claude-haiku-4-5-20251001
Bristol-Myers Squibb's convertible preferred stock (BMYMP) is trading at $400.00 with a massive market capitalization of $1.82 trillion, indicating this is a major healthcare player. The stock carries a fair value estimate of $509.31, suggesting 27.3% upside potential, though the current dividend yield of just 0.05% provides minimal income. With a moderate SID score of 6.8/10 and a Buy consensus from analysts, this security presents a mixed but potentially rewarding opportunity for investors seeking exposure to a large-cap healthcare company.
The P/E ratio of 17.28 indicates the stock is trading at a reasonable valuation relative to earnings, positioning it as neither significantly overvalued nor undervalued. Factor grades reveal concerning weaknesses in Value (D) and modest performance in Growth (C), Profitability (C), and Momentum (C), suggesting the company is maturing with limited explosive growth potential. The Dividend grade of B is noteworthy for a preferred convertible security, though the 0.05% yield is exceptionally low and unlikely to be a primary draw for income-focused investors. The absence of recent financial data and earnings reports limits the depth of fundamental analysis, making it difficult to assess current operational trends or near-term earnings trajectory.
Critical technical indicators are unavailable for this security, with RSI(14), 50-day moving average, and 200-day moving average all showing as not applicable or missing data. This absence of technical metrics significantly hampers the ability to assess momentum, trend direction, or support/resistance levels that typically guide short to intermediate-term trading decisions. The lack of price action data suggests either limited trading volume or data collection issues specific to this preferred convertible instrument. Without these technical tools, investors must rely more heavily on fundamental analysis and sentiment indicators.
Analyst & Insider Sentiment
The analyst consensus remains firmly in "Buy" territory, though the average price target is unavailable, limiting clarity on how aggressive this recommendation is relative to the 27.3% upside to fair value. Recent insider activity reveals mixed signals, with Short Bartie Wendy executing multiple sell transactions (20,121 shares total sold) on June 3, 2026, while simultaneously purchasing 15,957 shares the same day, suggesting potential portfolio rebalancing rather than conviction-driven selling. Adam Lenkowsky's sell transactions totaling 21,680 shares on May 1, 2026, without offsetting purchases, may indicate some insider skepticism about near-term price appreciation. The overall insider sentiment leans slightly negative despite the Buy consensus, creating a divergence worth monitoring.
The primary risk lies in the absence of current financial data and earnings information, making it impossible to validate whether the $509.31 fair value estimate remains justified or has become outdated. The extremely low dividend yield (0.05%) leaves minimal margin of safety for income investors, and the convertible nature introduces additional complexity around conversion pricing and dilution potential. Insider selling activity, while not dramatic, suggests some insiders may be taking profits or reducing exposure, which contradicts the positive analyst consensus and could foreshadow underperformance. The weak Value grade and missing technical indicators indicate limited visibility into both fundamental strength and momentum support.
Bristol-Myers Squibb's convertible preferred stock represents a moderate-conviction buy opportunity for investors who believe in the company's long-term healthcare business fundamentals and can tolerate the minimal income component. The 27.3% upside to fair value provides meaningful appreciation potential, supported by analyst Buy ratings, though the weak Value factor grade suggests investors should wait for better entry points or stronger conviction signals. This security is best suited for growth-oriented investors with a multi-year time horizon rather than income seekers, given the negligible 0.05% dividend yield. Before committing capital, investors should seek updated financial data, clarify the conversion terms, and monitor insider activity more closely to ensure alignment between analyst sentiment and management's actual confidence in the stock's trajectory.
